share_log

Teladoc Health | 10-Q: Q3 2024 Earnings Report

Teladoc Health | 10-Q: Q3 2024 Earnings Report

Teladoc Health | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/31 22:25

Moomoo AI 已提取核心訊息

Teladoc Health reported Q3 2024 revenue of $640.5 million, down 3% year-over-year, primarily due to weakness in its BetterHelp segment. The company's net loss narrowed to $33.3 million from $57.1 million in Q3 2023. Access fees, representing 87% of total revenue, declined 5% to $555.3 million, while other revenue increased 9% to $85.2 million.The Integrated Care segment showed resilience with revenue growing 2% to $383.7 million, driven by higher U.S. visit revenue and strong international growth. U.S. Integrated Care members increased 4% to 93.9 million. However, the BetterHelp segment struggled with revenue falling 10% to $256.8 million as average monthly paying users decreased 13% to 398,000.The company maintained strong liquidity with $1.24 billion in cash and cash equivalents as of September 30, 2024. Operating cash flow remained positive at $207.8 million for the nine months ended September 30, 2024. Management expects continued positive operating cash flow results for 2024, with sufficient resources to meet working capital needs for at least the next 12 months.
Teladoc Health reported Q3 2024 revenue of $640.5 million, down 3% year-over-year, primarily due to weakness in its BetterHelp segment. The company's net loss narrowed to $33.3 million from $57.1 million in Q3 2023. Access fees, representing 87% of total revenue, declined 5% to $555.3 million, while other revenue increased 9% to $85.2 million.The Integrated Care segment showed resilience with revenue growing 2% to $383.7 million, driven by higher U.S. visit revenue and strong international growth. U.S. Integrated Care members increased 4% to 93.9 million. However, the BetterHelp segment struggled with revenue falling 10% to $256.8 million as average monthly paying users decreased 13% to 398,000.The company maintained strong liquidity with $1.24 billion in cash and cash equivalents as of September 30, 2024. Operating cash flow remained positive at $207.8 million for the nine months ended September 30, 2024. Management expects continued positive operating cash flow results for 2024, with sufficient resources to meet working capital needs for at least the next 12 months.
Teladoc Health報告2024年第三季度營業收入爲64050萬美元，同比下降3%，主要由於BetterHelp部門的疲軟。公司的淨虧損從2023年第三季度的5710萬美元收窄至3330萬美元。佔總營業收入87%的接入費用下降5%，降至55530萬美元，而其他營業收入增長9%，達到8520萬美元。綜合護理部門表現出韌性，營業收入增長2%，達到38370萬美元，得益於美國就診收入增加和強勁的國際增長。美國綜合護理成員增加4%，達9390萬。然而，BetterHelp部門表現不佳，營業收入下降10%，降至25680萬美元，平均月付費用戶下降13%，降至398,000。截至2024年9月30日，公司保持強勁的流動性，現金及現金等價物爲12.4億。2024年9月30日結束的九個月內，經營現金流仍爲正，達到20780萬美元。管理層預計2024年將繼續保持正的經營現金流，擁有足夠的資源以滿足未來至少12個月的營運資金需求。
Teladoc Health報告2024年第三季度營業收入爲64050萬美元，同比下降3%，主要由於BetterHelp部門的疲軟。公司的淨虧損從2023年第三季度的5710萬美元收窄至3330萬美元。佔總營業收入87%的接入費用下降5%，降至55530萬美元，而其他營業收入增長9%，達到8520萬美元。綜合護理部門表現出韌性，營業收入增長2%，達到38370萬美元，得益於美國就診收入增加和強勁的國際增長。美國綜合護理成員增加4%，達9390萬。然而，BetterHelp部門表現不佳，營業收入下降10%，降至25680萬美元，平均月付費用戶下降13%，降至398,000。截至2024年9月30日，公司保持強勁的流動性，現金及現金等價物爲12.4億。2024年9月30日結束的九個月內，經營現金流仍爲正，達到20780萬美元。管理層預計2024年將繼續保持正的經營現金流，擁有足夠的資源以滿足未來至少12個月的營運資金需求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Performant Healthcare
    PHLT
    -- 3.000
    SHL Telemedicine
    SHLT
    -- 1.950
    Simulations Plus
    SLP
    -- 24.290
    Mangoceuticals
    MGRX
    -- 2.380
    Forian
    FORA
    -- 2.000
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點